Lang Wu
Research Subjects
Research Interests
Lang Wu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Asilbek Dauletbaev
Department of Chemistry and Biology, Kimyo International University, Tashkent, Uzbekistan
1 shared publication - Gulnoza Qurbonova
Department of Psychology and Medicine, Mamun University, Khiva, Uzbekistan
1 shared publication - Gulnoza Tashtemirova
Department of Public Health and Healthcare Management, Rector, Samarkand State Medical University, Samarkand, Uzbekistan
1 shared publication - Khaled Fahmi Fawy
Research Center for Advanced Materials Science (RCAMS), King Khalid University, Abha, Saudi Arabia
1 shared publication - Lakshmaiya Natrayan
Department of Mechanical Engineering, Saveetha School of Engineering, SIMATS, Chennai, India
1 shared publication - Mustafa Jawad Kadham
Al-Farahidi University, Baghdad, Iraq
1 shared publication
Latest Publications
- 3 February 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2449-2467
The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials
Despite advances in patients’ healthcare, gastric cancer remains a major health concern around the world with a high annual incidence rate and mortality. This highlights the urgent need to develop more effective therapeutic strategies, particularly for patients in advanced stages of the disease. In the recent decade, cellular-based immunotherapy has achieved remarkable successes in various hematologic malignancies and solid tumors. Nonetheless, until now, no cellular-based immunotherapy has been approved for GC patients. This review aims to provide a holistic view of the current state of cellular-based immunotherapy for GC, its existing bottlenecks, and future directions to harness the potential of cellular-based immunotherapy for GC treatment. In this regard, we explore clinical trials of various types of cellular-based immunotherapy, including chimeric antigen receptor (CAR)-engineered cell therapy, T cell receptor (TCR)-engineered T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, cytokine-induced killer (CIK) cell therapy, and dendritic cell (DC) vaccines. For each type of cellular-based immunotherapy, we discuss existing roadblocks to successful treatment and explore potential solutions that may improve efficacy, including novel targets, combination approaches, and biomarker-driven patient selection.
- 3 February 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2449-2467
The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials
Despite advances in patients’ healthcare, gastric cancer remains a major health concern around the world with a high annual incidence rate and mortality. This highlights the urgent need to develop more effective therapeutic strategies, particularly for patients in advanced stages of the disease. In the recent decade, cellular-based immunotherapy has achieved remarkable successes in various hematologic malignancies and solid tumors. Nonetheless, until now, no cellular-based immunotherapy has been approved for GC patients. This review aims to provide a holistic view of the current state of cellular-based immunotherapy for GC, its existing bottlenecks, and future directions to harness the potential of cellular-based immunotherapy for GC treatment. In this regard, we explore clinical trials of various types of cellular-based immunotherapy, including chimeric antigen receptor (CAR)-engineered cell therapy, T cell receptor (TCR)-engineered T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, cytokine-induced killer (CIK) cell therapy, and dendritic cell (DC) vaccines. For each type of cellular-based immunotherapy, we discuss existing roadblocks to successful treatment and explore potential solutions that may improve efficacy, including novel targets, combination approaches, and biomarker-driven patient selection.